We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ViaCyte

News List

ViaCyte, Gore to Develop Technologies that Enhance Delivery of Therapies for Diabetes americanpharmaceuticalreview
March 05, 2021
ViaCyte and W. L. Gore & Associates announced the two companies have signed an expanded joint development agreement covering the development and use of proprietary Gore materials and device capabilities to further optimize ViaCyte's portfolio of ...
ViaCyte Announces Initiation of Encapsulated Cell Therapy Study for Type 1 Diabetes americanpharmaceuticalreview
February 08, 2021
ViaCyte announced that the first type 1 diabetes (T1D) patients have been implanted in a Phase 2 clinical study utilizing encapsulated delivery of cells.
Center for Beta Cell Therapy in Diabetes, ViaCyte Announce Start of European Clinical Trial of Human Stem Cell-derived Implants americanpharmaceuticalreview
January 23, 2019
The Center for Beta Cell Therapy in Diabetes and ViaCyte announced a human stem cell-derived product candidate has been implanted in type 1 diabetes patients at a subtherapeutic dose.....
ViaCyte Secures $80 Million Financing for Insulin-Requiring Diabetes biospectrumasia
December 03, 2018
Clinical stage regenerative medicine company has announced an $80 million Series D financing led by Bain Capital Life Sciences and joined by TPG and RA Capital Management, as well as existing investor